Conatus Pharmaceuticals Inc.

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17

Role: collaborator

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

Role: collaborator

Caspase Inhibition in Islet Transplantation

Role: collaborator

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

Role: lead

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

Role: lead

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Role: lead

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

Role: lead

A Study of IDN-6556 in Subjects With Liver Cirrhosis

Role: lead

A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Role: lead

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

Role: lead

A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

Role: lead

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Role: lead

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

Role: lead

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

Role: lead

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Role: lead

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Role: lead

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Role: lead

Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders

Role: lead

CTS-1027 in Interferon-Naive Hepatitis C Patients

Role: lead

Study of CTS-1027 in Hepatitis C Patients

Role: lead